BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Méndez-Navarro J, Corey KE, Zheng H, Barlow LL, Jang JY, Lin W, Zhao H, Shao RX, McAfee SL, Chung RT. Hepatitis B screening, prophylaxis and re-activation in the era of rituximab-based chemotherapy. Liver Int 2011;31:330-9. [PMID: 20738779 DOI: 10.1111/j.1478-3231.2010.02332.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 2.7] [Reference Citation Analysis]
Number Citing Articles
1 Tang Z, Li X, Wu S, Liu Y, Qiao Y, Xu D, Li J. Risk of hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients with undetectable serum HBV DNA after treatment with rituximab for lymphoma: a meta-analysis. Hepatol Int. 2017;11:429-433. [PMID: 28856548 DOI: 10.1007/s12072-017-9817-y] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.6] [Reference Citation Analysis]
2 Vassilopoulos D, Calabrese LH. Management of rheumatic disease with comorbid HBV or HCV infection. Nat Rev Rheumatol 2012;8:348-57. [DOI: 10.1038/nrrheum.2012.63] [Cited by in Crossref: 44] [Cited by in F6Publishing: 38] [Article Influence: 4.4] [Reference Citation Analysis]
3 Tsutsumi Y, Yamamoto Y, Ito S, Ohigashi H, Shiratori S, Naruse H, Teshima T. Hepatitis B virus reactivation with a rituximab-containing regimen. World J Hepatol 2015; 7(21): 2344-2351 [PMID: 26413224 DOI: 10.4254/wjh.v7.i21.2344] [Cited by in Crossref: 38] [Cited by in F6Publishing: 30] [Article Influence: 5.4] [Reference Citation Analysis]
4 Desales AL, Mendez-navarro J, Méndez-tovar LJ, Ortiz-olvera NX, Cullen G, Ocampo J, Lemus W, Tun AE, Mayoral-zavala A, Dehesa-violante M. Pneumocystosis in a patient with Crohn's disease treated with combination therapy with adalimumab. Journal of Crohn's and Colitis 2012;6:483-7. [DOI: 10.1016/j.crohns.2011.10.012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
5 Sampedro B, Hernández-López C, Ferrandiz JR, Illaro A, Fábrega E, Cuadrado A, Iruzubieta P, Menéndez S, Cabezas J, Crespo J. Computerized physician order entry-based system to prevent HBV reactivation in patients treated with biologic agents: the PRESCRIB project. Hepatology. 2014;60:106-113. [PMID: 24585503 DOI: 10.1002/hep.27103] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.5] [Reference Citation Analysis]
6 Huang YW, Chung RT. Management of hepatitis B reactivation in patients receiving cancer chemotherapy. Therap Adv Gastroenterol. 2012;5:359-370. [PMID: 22973419 DOI: 10.1177/1756283X12450245] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
7 Felis-Giemza A, Olesińska M, Świerkocka K, Więsik-Szewczyk E, Haładyj E. Treatment of rheumatic diseases and hepatitis B virus coinfection. Rheumatol Int 2015;35:385-92. [PMID: 25549599 DOI: 10.1007/s00296-014-3195-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
8 Meyer-Olson D, Hoeper K, Schmidt RE. [Infectious complications of biologic therapy in patients with rheumatoid arthritis]. Z Rheumatol 2010;69:879-88. [PMID: 21128049 DOI: 10.1007/s00393-010-0677-2] [Cited by in Crossref: 6] [Article Influence: 0.5] [Reference Citation Analysis]
9 Hsu C, Tsou HH, Lin SJ, Wang MC, Yao M, Hwang WL, Kao WY, Chiu CF, Lin SF, Lin J, Chang CS, Tien HF, Liu TW, Chen PJ, Cheng AL;  Taiwan Cooperative Oncology Group. Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study. Hepatology. 2014;59:2092-2100. [PMID: 24002804 DOI: 10.1002/hep.26718] [Cited by in Crossref: 179] [Cited by in F6Publishing: 163] [Article Influence: 22.4] [Reference Citation Analysis]
10 Vassilopoulos D, Calabrese LH. Viral hepatitis: review of arthritic complications and therapy for arthritis in the presence of active HBV/HCV. Curr Rheumatol Rep. 2013;15:319. [PMID: 23436024 DOI: 10.1007/s11926-013-0319-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
11 Tsutsumi Y, Yamamoto Y, Shimono J, Ohhigashi H, Teshima T. Hepatitis B virus reactivation with rituximab-containing regimen. World J Hepatol 2013; 5(11): 612-620 [PMID: 24303089 DOI: 10.4254/wjh.v5.i11.612] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
12 Viganò M, Mangia G, Lampertico P. Management of patients with overt or resolved hepatitis B virus infection undergoing rituximab therapy. Expert Opinion on Biological Therapy 2014;14:1019-31. [DOI: 10.1517/14712598.2014.912273] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
13 Hay AE, Meyer RM. Hepatitis B, rituximab, screening, and prophylaxis: effectiveness and cost effectiveness. J Clin Oncol. 2012;30:3155-3157. [PMID: 22891267 DOI: 10.1200/jco.2012.43.7509] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
14 Mohsen W, Levy MT. Hepatitis A to E: what's new? Intern Med J 2017;47:380-9. [PMID: 28401719 DOI: 10.1111/imj.13386] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
15 Vassilopoulos D. Should we routinely treat patients with autoimmune/rheumatic diseases and chronic hepatitis B virus infection starting biologic therapies with antiviral agents? Yes. Eur J Intern Med. 2011;22:572-575. [PMID: 22075282 DOI: 10.1016/j.ejim.2011.09.001] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
16 Merli M, Rattotti S, Gotti M, Arcaini L. Antiviral therapies for managing viral hepatitis in lymphoma patients. Expert Opin Pharmacother 2017;18:363-76. [PMID: 28140702 DOI: 10.1080/14656566.2017.1288718] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
17 Axiaris G, Zampeli E, Michopoulos S, Bamias G. Management of hepatitis B virus infection in patients with inflammatory bowel disease under immunosuppressive treatment. World J Gastroenterol 2021; 27(25): 3762-3779 [PMID: 34321842 DOI: 10.3748/wjg.v27.i25.3762] [Reference Citation Analysis]
18 Huang YW, Chung RT. Management of hepatitis B reactivation in patients receiving cancer chemotherapy. Therap Adv Gastroenterol. 2012;5:359-370. [PMID: 22973419 DOI: 10.1177/1756283x1245024510.1177_1756283x12450245] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
19 Yilmaz B, Erdem D, Teker F, Goren I, Yildirim B, Kut E, Sarikaya D, Atay MH, Yucel I. The effect of anticancer therapy on anti-hepatitis B antibody titres in patients with haematological malignancies and solid tumours. J Int Med Res 2016;44:627-38. [PMID: 27048386 DOI: 10.1177/0300060516638992] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
20 Cao X, Wang Y, Li P, Huang W, Lu X, Lu H. HBV Reactivation During the Treatment of Non-Hodgkin Lymphoma and Management Strategies. Front Oncol 2021;11:685706. [PMID: 34277431 DOI: 10.3389/fonc.2021.685706] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
21 Zachou K, Dalekos GN. Hepatitis B re-activation with rituximab therapy: treat the patient not the disease. Liver Int. 2011;31:277-279. [PMID: 21281426 DOI: 10.1111/j.1478-3231.2011.02452.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
22 Mozessohn L, Chan KK, Feld JJ, Hicks LK. Hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients receiving rituximab for lymphoma: a meta-analysis. J Viral Hepat. 2015;22:842-849. [PMID: 25765930 DOI: 10.1111/jvh.12402] [Cited by in Crossref: 79] [Cited by in F6Publishing: 72] [Article Influence: 11.3] [Reference Citation Analysis]
23 Hwang JP, Fisch MJ, Lok AS, Zhang H, Vierling JM, Suarez-Almazor ME. Trends in hepatitis B virus screening at the onset of chemotherapy in a large US cancer center. BMC Cancer 2013;13:534. [PMID: 24209764 DOI: 10.1186/1471-2407-13-534] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
24 Civan J, Hann HW. Giving rituximab in patients with occult or resolved hepatitis B virus infection: are the current guidelines good enough? Expert Opin Drug Saf. 2015;14:865-875. [PMID: 25826452 DOI: 10.1517/14740338.2015.1032243] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
25 Hwang JP, Vierling JM, Zelenetz AD, Lackey SC, Loomba R. Hepatitis B virus management to prevent reactivation after chemotherapy: a review. Support Care Cancer. 2012;20:2999-3008. [PMID: 22933131 DOI: 10.1007/s00520-012-1576-7] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
26 Sandherr M, Hentrich M, von Lilienfeld-Toal M, Massenkeil G, Neumann S, Penack O, Biehl L, Cornely OA. Antiviral prophylaxis in patients with solid tumours and haematological malignancies--update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO). Ann Hematol 2015;94:1441-50. [PMID: 26193852 DOI: 10.1007/s00277-015-2447-3] [Cited by in Crossref: 65] [Cited by in F6Publishing: 45] [Article Influence: 9.3] [Reference Citation Analysis]
27 Bath RM, Doering BE, Nailor MD, Goodlet KJ. Pharmacotherapy-Induced Hepatitis B Reactivation Among Patients With Prior Functional Cure: A Systematic Review. Ann Pharmacother 2019;53:294-310. [PMID: 30203666 DOI: 10.1177/1060028018800501] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
28 Liu Y, Kong XJ, Jiang YJ, Wu J, Li XH, Tian ZB. Reactivation of hepatitis B virus and antiviral treatment in cancer patients receiving chemotherapy. Shijie Huaren Xiaohua Zazhi 2013; 21(11): 1050-1054 [DOI: 10.11569/wcjd.v21.i11.1050] [Reference Citation Analysis]
29 Viganò M, Serra G, Casella G, Grossi G, Lampertico P. Reactivation of hepatitis B virus during targeted therapies for cancer and immune-mediated disorders. Expert Opin Biol Ther 2016;16:917-26. [PMID: 27088278 DOI: 10.1080/14712598.2016.1177017] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.5] [Reference Citation Analysis]